SecBot SecBot
Biotech Drug Report Generated Nov 13, 2026

ZORYVE

ARQT·Arcutis Biotherapeutics, Inc.
BULLISH
Drug Impact Rating7/10
Trial phase
Approved (commercial stage)
Time to market
Already approved and commercialized. The next label expansion (infant atopic dermatitis) has a PDUFA decision date of February 23, 2027.
Why 7/10
The next hard catalyst is the FDA PDUFA decision on February 23, 2027 for the sNDA expanding ZORYVE cream 0.05% to infants aged 3-24 months with atopic dermatitis. This is a label expansion for an already-approved, revenue-generating drug, so the binary outcome is meaningful but not make-or-break for the company. ImpactScore 7 reflects a dated binary within ~6 months on the company's lead asset that drives most of the thesis.
Actionable Insight BULLISH

The next hard catalyst is the FDA PDUFA decision on February 23, 2027 for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis. Approval would expand the addressable patient population and support the company's 2027 revenue inflection narrative; a CRL would remove that near-term growth driver but not threaten the core commercial business, which is already generating over $500M in annual revenue.

Price Chart

Loading chart...

Executive Summary

ZORYVE (roflumilast) is Arcutis Biotherapeutics' (ARQT) only marketed product, a once-daily topical steroid-free PDE4 inhibitor approved in cream and foam formulations for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. The drug is already generating substantial and growing revenue ($143.9M in Q3 2026, up 45% YoY) with full-year 2026 guidance raised to $535-545M. The next major catalyst is the FDA PDUFA decision on February 23, 2027 for label expansion of ZORYVE cream 0.05% to infants aged 3-24 months with atopic dermatitis. The company is also advancing a Phase 3 trial in moderate to severe atopic dermatitis and a Phase 2 trial in chronic hand eczema. Analyst consensus is strongly bullish (12 Buy/Strong Buy, mean PT $40.38, 46.7% upside), though insider selling and competitive pressure are notable risks.

How It Works

ZORYVE (roflumilast) is a topical cream or foam that you apply directly to the skin. It works by blocking an enzyme called PDE4, which reduces inflammation in the skin. Unlike steroid creams, it is steroid-free and can be used on any part of the body without restrictions on how long it can be used. It is applied once daily.

Trial Status

ZORYVE is approved across multiple indications and formulations. The sNDA for infant atopic dermatitis (ages 3-24 months) is under FDA review with a PDUFA date of February 23, 2027. A Phase 3 trial (INTEGUMENT-3) for ZORYVE cream 0.3% in moderate to severe atopic dermatitis began enrolling in November 2026. A Phase 2 trial of ZORYVE foam 0.3% for chronic hand eczema is ongoing with topline results on track.

The Two-Sided Case

▲ Bull Case5
Strong commercial momentum: ZORYVE net product revenue reached $143.9M in Q3 2026, up 45% year-over-year and 11% sequentially, with full-year 2026 guidance raised to $535-545 million.
Expanding label: ZORYVE is now approved across three major inflammatory skin conditions (plaque psoriasis, atopic dermatitis, seborrheic dermatitis) with multiple formulations (cream 0.3%, 0.15%, 0.05% and foam 0.3%), making it the #1 prescribed branded topical therapy across these indications.
Upcoming PDUFA catalyst: The FDA accepted the sNDA for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis, with a PDUFA date of February 23, 2027, which could open a new patient population.
Strong institutional support: 12 Buy/Strong Buy analyst ratings vs 2 Hold, with a mean price target of $40.38 (46.7% upside from the current ~$27.53). Q3 2026 13F filings showed broad institutional accumulation including State Street (+32.6%), UBS (+66%), and new positions from Public Sector Pension Investment Board.
Pipeline expansion: Phase 3 INTEGUMENT-3 trial began enrolling for ZORYVE cream 0.3% in moderate to severe atopic dermatitis, and a Phase 2 trial in chronic hand eczema is on track for topline data.
▼ Bear Case4
Insider selling: Multiple executives (CEO Todd Watanabe, CMO Patrick Burnett, CLO Masaru Matsuda) sold shares in early November 2026 near $31-34, near the top of the 52-week range, per SEC Form 4 filings.
EPS miss: Arcutis missed Q3 2026 earnings expectations as SG&A spending jumped to $99.6M (from $62.4M a year ago) to fund sales force expansion, pressuring near-term profitability.
Competitive pressure: ZORYVE faces competition from topical steroids, other PDE4 inhibitors, and JAK inhibitors in dermatology; a Seeking Alpha analyst downgraded the stock to Hold citing intense competition and slow growth.
Valuation multiple compression: Despite strong revenue growth, the stock has seen multiple compression as noted by analysts, with the stock trading around $27-28 versus the mean analyst price target of $40.

Upcoming Catalysts

  • FDA PDUFA decision on February 23, 2027 for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis
  • Topline results from Phase 2 trial of ZORYVE foam 0.3% for chronic hand eczema (timing not specified but 'on track' per Q3 2026 update)
  • Enrollment and potential interim data from Phase 3 INTEGUMENT-3 trial of ZORYVE cream 0.3% in moderate to severe atopic dermatitis

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Arcutis Biotherapeutics, Inc. Press Release ARQT ·Originating report

Sources · 14

Hover a chip for the title
1 markets.businessinsider.com2 healio.com3 empr.com4 ajmc.com5 seekingalpha.com6 seekingalpha.com7 markets.businessinsider.com8 biospace.com9 msn.com10 sec.gov11 sec.gov12 sec.gov13 wboc.com14 morningstar.com